摘要
Abstract
Objective To investigate the relationship of clinical efficacy of icotinib with clinical features of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitizing gene mutation.Methods A total of 104 patients diagnosed as advanced NSCLC with EGFR sensitizing gene mutation were enrolled,and were orally administrated icotinib.Objective response rate (ORR) and disease control rate (DCR) were evaluated after four weeks of treatment.Progression-free survival (PFS) was assessed at the end of follow-up.The relationship of clinical features with ORR,DCR or PFS was analyzed.The incidence of adverse reactions was observed.Results The ORR and DCR of the 104 patients were 48.1％ and 87.0％,respectively.The ORRs of the patients with exon 19 deletion of EGFR,icotinib as first-line therapy,and rashes were higher than those of the patients with 21L858R mutation of EGFR,icotinib as second-line therapy,and without rashes,respectively(P ＜ 0.05).The DCRs of the patients with 0-1 scores of physical status,adenocarcinoma,exon 19 deletion of EGFR,and first-line therapy were higher than those of the patients with 2-4 scores of physical status,non adenocarcinoma,21L858R mutation of EGFR,and second-line therapy,respectively(P ＜ 0.05).The median PFS of the 104 patients was 10.6 months.The PFS of the patients with 0-1 score of physical status,non smoking,exon 19 deletion of EGFR,first-line therapy,and rashes were longer than those of the patients with 2-4 scores of physical status,smoking,21L858R mutation of EGFR,second-line therapy,and without rashes,respectively (P ＜ 0.05).The common drug-related adverse reactions were rashes (26.9％),diarrhea (13.4％) and aminotransferase elevation (9.6％),and no special treatment was performed in any case.Conclusion Icotinib has mild adverse reactions in the treatment of patients diagnosed as advanced NSCLC with EGFR sensitizing mutation,and it achieves better short-and long-term efficacy for patients with exon 19 deletion of EGFR,rashes during treatment,and first-line therapy.关键词
非小细胞肺癌/埃克替尼/表皮生长因子受体基因/敏感突变/疗效/临床特征Key words
Non-small cell lung cancer/Icotinib/Epidermal growth factor receptor gene/Sensitizing mutation/Efficacy/Clinical feature分类
医药卫生
